12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Other News

Teva, Mylan autoimmune, generics news

Teva and Mylan settled patent litigation in the U.K., the Netherlands and France involving Teva's multiple sclerosis drug Copaxone glatiramer acetate and European Patent No. 0,762,888, which expires in May 2015. The terms of the settlement are not disclosed. Teva recorded $3.2 billion in worldwide Copaxone...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >